SAN FRANCISCO — The California Supreme Court on Wednesday said it would take up a challenge to so-called “pay for delay” pharmaceutical settlements.
A class of consumers asked the high court to review a sweeping Fourth District Court of Appeal ruling that OK’d a $398.1 million payment Bayer AG, patent holder of the antibiotic Cipro, made to Barr Laboratories and other competitors to delay the introduction of cheaper generic versions in In re Cipro Cases I & II.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
